InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Discover the complete record of transactions filed by Hannah Alison l., Director. Officer active across 4 companies, notably Neogenomics INC. Cumulatively, 13 disclosures have been recorded. History available since 19 May 2021. The latest transaction was disclosed on 8 July 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Hannah Alison l.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations13 total
24,400 shares0Common StockSEC:0000905148-26-003238:0
12,254 shares0Common StockSEC:0001077183-25-000126:0
12,254 shares0Common StockSEC:0001077183-25-000132:0
2,500 shares0Common StockSEC:0000905148-25-001932:0
11,336 shares0Common StockSEC:0001077183-24-000127:0
25,000 shares0Common StockSEC:0000905148-24-001652:0
25,000 shares0Common StockSEC:0001140361-23-034282:0
15,000 shares0Common StockSEC:0001567619-22-014297:0
15,556 shares0Common StockSEC:0001077183-22-000110:0
25,000 shares0Common StockSEC:0001140361-22-020304:0
22,500 shares0Common StockSEC:0001567619-22-002523:0
3,081 shares0Common StockSEC:0001077183-21-000162:0
6,250 shares0Common StockSEC:0001179110-21-005772:0
13 of 13 declarations
About Hannah Alison l.
Alison L. Hannah is a Board Member and Chief Medical Officer at NEOGENOMICS INC and RIGEL PHARMACEUTICALS INC. She oversees medical affairs and contributes to the company's strategy. Hannah plays a key role in innovation and the development of new treatments.
